Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 475 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Young Woman Considers Service Dog A Crucial Ally In Her Battle... July 20, 2020 Cancer Research UK announces appointment of new Chair March 28, 2023 Working to Close the Cancer Screening Gap Caused by COVID May 17, 2022 Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 Load more HOT NEWS Cancer Researchers Bring Tools, Experience to COVID-19 Studies Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de...
